NASDAQ: CLLS - Cellectis S.A.

Yield per half year: -21.84%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Cellectis S.A.

Extended chart Simple chart
Financial Markets by TradingView

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

more details
It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2007-02-07
ISIN US15117K1034
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cellectis.com
Цена ао 1.3
Change price per day: -1% (1.5)
Change price per week: +21.92% (1.218)
Change price per month: +19.76% (1.24)
Change price per 3 month: -11.61% (1.68)
Change price per half year: -21.84% (1.9)
Change price per year: -43.1% (2.61)
Change price per 3 year: -65.63% (4.32)
Change price per 5 year: -82.3% (8.39)
Change price per year to date: -6.6% (1.59)
All parameters

Underestimation

Title Value Grade
P/S 4.39 4
P/BV 1.39 9
P/E 0 0
EV/EBITDA -1.76 0
Total: 5.13

Efficiency

Title Value Grade
ROA, % -10.24 0
ROE, % -34.08 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.5542 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % -43.83 0
Yield Ebitda, % -25.05 0
Yield EPS, % -78.52 0
Total: 0
More

Institutions Volume Share, %
Long Focus Capital Management, LLC 4487293 6.25
Capital International Investors 1848804 2.58
Credit Suisse Ag/ 1438255 2
Baillie Gifford and Company 816643 1.14
Principal Financial Group, Inc. 399627 0.56
Macquarie Group Limited 226875 0.32
KBC Group NV 163447 0.23
Oppenheimer & Company Inc. 133143 0.19
Morgan Stanley 76225 0.11
LPL Financial LLC 72187 0.1



Head Job title Payment Year of birth
Dr. Andre Choulika Ph.D. Co-Founder, CEO & Director 876.6k 1965 (60 years)
Valerie Cros Principal Financial Officer & Principal Accounting Officer N/A
Mr. Jean Charles Epinat Chief Technological Officer N/A
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer N/A 1963 (62 years)
Mr. Stephan Reynier M.Sc. Chief Regulatory & Pharmaceutical Compliance Officer N/A 1969 (56 years)
Ms. Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors N/A 1982 (43 years)
Pascalyne Wilson Director of Communications N/A
Ms. Kyung Nam-Wortman Executive VP & Chief Human Resources Officer N/A 1970 (55 years)
Dr. David j. d. Sourdive Ph.D. Deputy CEO, Executive VP of CMC & Manufacturing and Director 557.84k 1967 (58 years)
Mr. Arthur Stril Interim Chief Financial Officer 1989 (36 years)

Address: France, Paris, 8. rue de la Croix Jarry - open in Google maps, open in Yandex maps
Website: https://www.cellectis.com